Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NexGard Combo
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim Animal Health
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
NexGard Combo is a topical broad-spectrum endectoparasiticide developed by Boehringer Ingelheim for feline use. It is a fixed-dose combination of three active ingredients: esafoxolaner, a purified enantiomer of afoxolaner that targets GABA receptors to provide insecticidal and acaricidal activity; eprinomectin, a macrocyclic lactone that binds to glutamate-gated chloride channels to treat nematode infections and prevent heartworm disease; and praziquantel, a cestocide that alters membrane permeability and calcium homeostasis to treat tapeworms. Approved by the U.S. FDA in 2023, it is indicated for the treatment and control of fleas, ticks, ear mites, roundworms, hookworms, and tapeworms, as well as the prevention of heartworm disease in cats.
- Brand names
- NexGard Combo
- Other names
- esafoxolaner + eprinomectin + praziquantel
02
Targets
CaV (Voltage-gated calcium channel protein complex)GluCl (Glutamate-gated chloride channel)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)
Beyond the preview
Go deeper on NexGard Combo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NexGard Combo.